HOME > NATION > Article

Text Size

small

medium

large


(Update) Fujifilm Unit to Apply for Avigan Use for Coronavirus

(Update) Fujifilm Unit to Apply for Avigan Use for Coronavirus

   Tokyo, Sept. 23 (Jiji Press)--A Fujifilm Holdings Corp. <4901> subsidiary said Wednesday it will submit an application to the Japanese health ministry as early as October to seek approval for the use of influenza drug Avigan for patients with the novel coronavirus.
   Fujifilm Toyama Chemical Co., which developed the drug, confirmed in its clinical tests on COVID-19 patients in Japan that the drug is effective, to some extent, in treating patients with the respiratory disease caused by the new coronavirus.
   If approved, it would be the first Japanese-developed COVID-19 treatment.
   The company began the clinical tests in March to confirm the safety and efficacy of Avigan, which has been approved in Japan as an antiflu drug, for patients with the new coronavirus.
   Tests on 156 novel coronavirus patients without severe symptoms found that those given the drug tested negative for the virus in polymerase chain reaction, or PCR, tests after 11.9 days on average, while the control group tested negative after an average of 14.7 days.

To read a full story, please click here to find out how to subscribe.

NATION

Aomori Tourism Information

HEADLINES

POLITICS
Paperback Edition of Suga's 2012 Book No Longer Puts Emphasis on Public Records
ECONOMY
Pfizer Starts Novel Coronavirus Vaccine Clinical Trial in Japan
SPORTS
Pro Baseball: Seibu Reliever Tomomi Takahashi, 31, Announces Retirement
OTHER
Tokyo Sees 139 New Coronavirus Cases

AFP-JIJI PRESS NEWS JOURNAL


Photos